Danaher Corp.

DHR-N

NYSE:DHR

255.89
2.97 (1.17%)
The Danaher Corporation is an American company with its headquarters in Washington, D.C., United States. Its products are concentrated in the fields of design, manufacturing, and marketing of industrial and consumer products.
More at Wikipedia

Analysis and Opinions about DHR-N

Signal
Opinion
Expert
Chart
BUY
BUY
April 16, 2021
They report Thursday. They have a high-growth healthcare business that they partly picked up from GE for a song. He expects a great quarter.
Show full opinionHide full opinion
Danaher Corp. (DHR-N)
April 16, 2021
They report Thursday. They have a high-growth healthcare business that they partly picked up from GE for a song. He expects a great quarter.
Jim Cramer - Mad Money
Price
$243.060
Owned
Unknown
DON'T BUY
DON'T BUY
March 19, 2021
A diversified industrial company in the life science and diagnostic services business. Has grown through acquisitions. Has made 2 dozens acquisitions in the past year. Bought GE's biopharma business. Relatively expensive at 40x earnings. Does not warrant this type of price tag. Nothing wrong but a little expensive for him.
Show full opinionHide full opinion
Danaher Corp. (DHR-N)
March 19, 2021
A diversified industrial company in the life science and diagnostic services business. Has grown through acquisitions. Has made 2 dozens acquisitions in the past year. Bought GE's biopharma business. Relatively expensive at 40x earnings. Does not warrant this type of price tag. Nothing wrong but a little expensive for him.
Gordon Reid
Price
$221.060
Owned
No
COMMENT
COMMENT
February 10, 2021

DHR vs. TMO vs. WAT WAT not performing as well as Thermo Fisher or Danaher. Cash from operations has been flat in the last 4 years, whereas the other two have doubled, which is reflected in the stock price. Market share, operating margins, and pricing power impact the business model. Compare these when assessing competitors in an industry.

Show full opinionHide full opinion
Danaher Corp. (DHR-N)
February 10, 2021

DHR vs. TMO vs. WAT WAT not performing as well as Thermo Fisher or Danaher. Cash from operations has been flat in the last 4 years, whereas the other two have doubled, which is reflected in the stock price. Market share, operating margins, and pricing power impact the business model. Compare these when assessing competitors in an industry.

David Driscoll
Price
$237.970
Owned
Yes
COMMENT
COMMENT
January 8, 2021

A fine long-term performer. They bought a biopharma asset from GE and will report on it in on Wednesday.

Show full opinionHide full opinion
Danaher Corp. (DHR-N)
January 8, 2021

A fine long-term performer. They bought a biopharma asset from GE and will report on it in on Wednesday.

Jim Cramer - Mad Money
Price
$243.490
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
September 16, 2020

(A Top Pick Oct 28/19, Up 54%) Covid is impacting them. They bought GE pharma division, and the timing couldn't be better. Grown dividend by 28% over the last 5 years, paying down debt.

Show full opinionHide full opinion
Danaher Corp. (DHR-N)
September 16, 2020

(A Top Pick Oct 28/19, Up 54%) Covid is impacting them. They bought GE pharma division, and the timing couldn't be better. Grown dividend by 28% over the last 5 years, paying down debt.

BUY
BUY
August 31, 2020
They produce consumables for drug production, a great company. For the discovery and production of drugs. They're in a unique situation, because their filtration systems also apply to industrial production.
Show full opinionHide full opinion
Danaher Corp. (DHR-N)
August 31, 2020
They produce consumables for drug production, a great company. For the discovery and production of drugs. They're in a unique situation, because their filtration systems also apply to industrial production.
David Fingold
Price
$206.350
Owned
Yes
WAIT
WAIT
August 25, 2020
Has long owned this. It's benefited from COVID, because DHR prrovides testing equipment. Their latest acquisition was huge, from GE's bio-farm unit. DHR is expensive now, but this is good for the long term. Buy only half or a third now and see what happens with volatility in the fall running up the U.S. election.
Show full opinionHide full opinion
Danaher Corp. (DHR-N)
August 25, 2020
Has long owned this. It's benefited from COVID, because DHR prrovides testing equipment. Their latest acquisition was huge, from GE's bio-farm unit. DHR is expensive now, but this is good for the long term. Buy only half or a third now and see what happens with volatility in the fall running up the U.S. election.
David Driscoll
Price
$207.150
Owned
Yes
WATCH
WATCH
April 20, 2020
It is rather like a 3-M, a healthcare services like company, diagnostics, etc. He thinks it is a fabulous company. Maybe you want to hold this for a longer period of time. Margins may be peaking, however. In the US healthcare is tied to employment. The dividend is actually quite small. You want to focus on this in the post-COVID-19 environment.
Show full opinionHide full opinion
Danaher Corp. (DHR-N)
April 20, 2020
It is rather like a 3-M, a healthcare services like company, diagnostics, etc. He thinks it is a fabulous company. Maybe you want to hold this for a longer period of time. Margins may be peaking, however. In the US healthcare is tied to employment. The dividend is actually quite small. You want to focus on this in the post-COVID-19 environment.
Darren Sissons
Price
$156.715
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
February 7, 2020

(A Top Pick Jan 17/19, Up 54%) A life-sciences companies that also does consumables and mass spectrometers. They recently purchased the GE biopharma section. They have big margins coming into the company. Earnings were higher than their peer group. He has owned this since 2013 and he sees no reason to sell it. He wouldn't enter now with 30x earnings. It works as a core holding since life science has good growth potential.

Show full opinionHide full opinion
Danaher Corp. (DHR-N)
February 7, 2020

(A Top Pick Jan 17/19, Up 54%) A life-sciences companies that also does consumables and mass spectrometers. They recently purchased the GE biopharma section. They have big margins coming into the company. Earnings were higher than their peer group. He has owned this since 2013 and he sees no reason to sell it. He wouldn't enter now with 30x earnings. It works as a core holding since life science has good growth potential.

David Driscoll
Price
$161.990
Owned
Yes
COMMENT
COMMENT
February 4, 2020
As a roll-up It was a roll-up, but not now. The new DHR is a producer of filtration systems and single-use consumables that help make biotech drugs. They have a leading market share, supplying most major biotechs around the world. He likes it. Little is built into the numbers now and investors are very conservative about forecasting the biotech drug market.
Show full opinionHide full opinion
Danaher Corp. (DHR-N)
February 4, 2020
As a roll-up It was a roll-up, but not now. The new DHR is a producer of filtration systems and single-use consumables that help make biotech drugs. They have a leading market share, supplying most major biotechs around the world. He likes it. Little is built into the numbers now and investors are very conservative about forecasting the biotech drug market.
David Fingold
Price
$163.290
Owned
Yes
SELL
SELL
January 13, 2020
They have been a successful franchise and acquisition story. His concern has always been valuation. This is a great company. It should be on your radar. It is too expensive so you should sell it.
Show full opinionHide full opinion
Danaher Corp. (DHR-N)
January 13, 2020
They have been a successful franchise and acquisition story. His concern has always been valuation. This is a great company. It should be on your radar. It is too expensive so you should sell it.
Darren Sissons
Price
$159.320
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
January 13, 2020
(A Top Pick Oct 28/19, Up 17%) It's up 52% in the past year, but $10,000 returned over 30 years is now $2.3 million!
Show full opinionHide full opinion
Danaher Corp. (DHR-N)
January 13, 2020
(A Top Pick Oct 28/19, Up 17%) It's up 52% in the past year, but $10,000 returned over 30 years is now $2.3 million!
TOP PICK
TOP PICK
October 28, 2019
A private equity company and a smart acquisitor. They bought GE's biopharma division which added debt to their books, but DHR has done buys like this before, knowing how to pay down debt yet be accretive to earnings. They have spun-off their dental division The dividend has grown 28% annually, though it is small now. Great for the long term. (Analysts’ price target is $152.14)
Show full opinionHide full opinion
Danaher Corp. (DHR-N)
October 28, 2019
A private equity company and a smart acquisitor. They bought GE's biopharma division which added debt to their books, but DHR has done buys like this before, knowing how to pay down debt yet be accretive to earnings. They have spun-off their dental division The dividend has grown 28% annually, though it is small now. Great for the long term. (Analysts’ price target is $152.14)
BUY
BUY
March 21, 2019
They just bought GE Pharma for $20 billion that supposedly is going to be an earnings accretive acquisition. The stock went up in price $6 the day it was announced. The market basically saying "you did good". Now they sit back and pay down the debt in 5 years. There is going to be a bump in earnings. Still buying but it is getting toppish.
Show full opinionHide full opinion
Danaher Corp. (DHR-N)
March 21, 2019
They just bought GE Pharma for $20 billion that supposedly is going to be an earnings accretive acquisition. The stock went up in price $6 the day it was announced. The market basically saying "you did good". Now they sit back and pay down the debt in 5 years. There is going to be a bump in earnings. Still buying but it is getting toppish.
David Driscoll
Price
$132.290
Owned
Yes
TOP PICK
TOP PICK
January 17, 2019
Life sciences, diagnostics, and consumables for research, with huge demographic potential. Multinational. Looking at 10-15% dividend growth. Has owned it for the better part of a decade and it's never upset him. Yield is 0.6% (Analysts’ price target is $112.53)
Show full opinionHide full opinion
Danaher Corp. (DHR-N)
January 17, 2019
Life sciences, diagnostics, and consumables for research, with huge demographic potential. Multinational. Looking at 10-15% dividend growth. Has owned it for the better part of a decade and it's never upset him. Yield is 0.6% (Analysts’ price target is $112.53)
David Driscoll
Price
$105.570
Owned
Yes
Showing 1 to 15 of 26 entries

Danaher Corp.(DHR-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 3

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 4

Stockchase rating for Danaher Corp. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Danaher Corp.(DHR-N) Frequently Asked Questions

What is Danaher Corp. stock symbol?

Danaher Corp. is a American stock, trading under the symbol DHR-N on the New York Stock Exchange (DHR). It is usually referred to as NYSE:DHR or DHR-N

Is Danaher Corp. a buy or a sell?

In the last year, 4 stock analysts published opinions about DHR-N. 3 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Danaher Corp..

Is Danaher Corp. a good investment or a top pick?

Danaher Corp. was recommended as a Top Pick by Jim Cramer - Mad Money on 2021-04-16. Read the latest stock experts ratings for Danaher Corp..

Why is Danaher Corp. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Danaher Corp. worth watching?

4 stock analysts on Stockchase covered Danaher Corp. In the last year. It is a trending stock that is worth watching.

What is Danaher Corp. stock price?

On 2021-04-23, Danaher Corp. (DHR-N) stock closed at a price of $255.89.